Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID

This publication has 41 references indexed in Scilit:

• Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
  The Lancet Rheumatology, 2020
• Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19
  American Journal of Respiratory and Critical Care Medicine, 2020
• Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
  Clinical Immunology, 2020
• Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients
  Proceedings of the National Academy of Sciences, 2020
• The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
  Clinical Immunology, 2020
• Compendium of current complement therapeutics
  Molecular Immunology, 2019
• The membrane attack complex as an inflammatory trigger
  Immunobiology, 2016
• Complementing the inflammasome
  Immunology, 2016
• Complement, a target for therapy in inflammatory and degenerative diseases
  Nature Reviews Drug Discovery, 2015
• Complement and its role in innate and adaptive immune responses
  Cell Research, 2009